Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB-031
- Development stage
- Phase 2
- Lead developer
- Basking Biosciences
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
BB-031 is a first-in-class RNA aptamer that targets the A1 domain of von Willebrand Factor (vWF), an important structural component of blood clots. It acts as a thrombolytic agent by inhibiting vWF, thereby preventing platelet adhesion and aggregation, which enables rapid recanalization of blocked blood vessels in acute thrombotic conditions such as ischemic stroke. The drug is designed for rapid onset and short duration of action, with its effects quickly neutralizable by a complementary reversal agent (BB-025) in case of bleeding. Developed by Basking Biosciences, BB-031 has demonstrated safety and tolerability in Phase 1 trials with healthy volunteers and is currently being evaluated in Phase 2 clinical trials for acute ischemic stroke. Preclinical studies have also shown potential efficacy in pulmonary embolism[1][2][3][4][5][7].
- Other names
- DTRI-031DTRI031DTRI 031BB-031BB031BB 031
02
Targets
BB-031 (Von Willebrand factor)
Beyond the preview
Go deeper on BB-031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB-031.